• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. Updated Management of Pediatric Heart Failure by Use of Nebulized Furosemide and Salbutamol

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Updated Management of Pediatric Heart Failure by Use of Nebulized Furosemide and Salbutamol

    Author

    • Hesham Mohamed Abdallah,Laila Raslan Abdelaziz, Al Shaymaa Ahmed Ali
,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

A congenital heart disease (CHD) is a defect in the structure of the heart and great vessels
which is present at birth. Many types of CHD exist, most of which either obstruct blood flow in
the heart or vessels near it, or cause blood to flow through the heart in an abnormal pattern.
Other diseases, such as long QT syndrome, affect the heart's rhythm. CHDs are among the most
common birth defects and are the leading cause of birth defect-related deaths. Approximately 9
people in 1000 are born with CHD. Many diseases do not need treatment, but some complex
CHD require medication or surgery. Heart failure in children is a clinical and
pathophysiological syndrome that results from ventricular dysfunction, volume or pressure
overload, either alone or in combination. Salbutamol is generally given via pressurized metered
dose inhaler (pMDI) with a large volume spacer, this is a highly efficient delivery system and
ensures good delivery particularly to the small-sized to moderate-sized airways. However, it can
also be inhaled via a dry powder inhaler or nebuliser or given orally or intravenously Inhaled
furosemide affects the respiratory system by inhibiting the movement of chlorine through the
membrane of the epithelial cell , also increases the synthesis and release of the bronchodilators
prostaglandin E2 (PGE2) in the airway epithelium and prostacycline (PGI2) in the vascular
endothelium.

Keywords

  • Nebulized Furosemide
  • Salbutamol
  • Congenital Heart Diseases (CHD)
  • Heart Failure (HF)
  • XML
  • PDF 313.25 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 192
    • PDF Download: 296
European Journal of Molecular & Clinical Medicine
Volume 8, Issue 3
February 2021
Page 4224-4237
Files
  • XML
  • PDF 313.25 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 192
  • PDF Download: 296

APA

Ali, H. M. A. R. A. A. S. A. (2021). Updated Management of Pediatric Heart Failure by Use of Nebulized Furosemide and Salbutamol. European Journal of Molecular & Clinical Medicine, 8(3), 4224-4237.

MLA

Hesham Mohamed Abdallah,Laila Raslan Abdelaziz, Al Shaymaa Ahmed Ali. "Updated Management of Pediatric Heart Failure by Use of Nebulized Furosemide and Salbutamol". European Journal of Molecular & Clinical Medicine, 8, 3, 2021, 4224-4237.

HARVARD

Ali, H. M. A. R. A. A. S. A. (2021). 'Updated Management of Pediatric Heart Failure by Use of Nebulized Furosemide and Salbutamol', European Journal of Molecular & Clinical Medicine, 8(3), pp. 4224-4237.

VANCOUVER

Ali, H. M. A. R. A. A. S. A. Updated Management of Pediatric Heart Failure by Use of Nebulized Furosemide and Salbutamol. European Journal of Molecular & Clinical Medicine, 2021; 8(3): 4224-4237.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus